Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$106.83
+2.1%
$102.74
$71.88
$107.17
$157.61B0.686.62 million shs15.64 million shs
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$379.00
+0.4%
$366.55
$289.98
$417.14
$91.25B1.491.47 million shs1.55 million shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$521.00
$554.18
$476.49
$1,211.20
$56.25B0.31899,578 shs1.61 million shs
Zoetis Inc. stock logo
ZTS
Zoetis
$156.17
+0.2%
$160.40
$139.70
$200.33
$69.53B0.942.56 million shs2.99 million shs
20 Stocks to Sell Now Cover

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.00%+5.40%+2.24%+7.59%+38.56%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
0.00%+0.46%+0.07%+10.74%+11.35%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.00%+2.21%-13.94%-18.26%-51.27%
Zoetis Inc. stock logo
ZTS
Zoetis
0.00%-0.69%-6.57%-4.21%-8.64%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Boston Scientific Corporation stock logo
BSX
Boston Scientific
4.1733 of 5 stars
2.63.00.04.22.82.51.3
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
4.7468 of 5 stars
2.43.02.54.52.82.52.5
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4.9328 of 5 stars
4.45.01.72.32.71.71.9
Zoetis Inc. stock logo
ZTS
Zoetis
4.8096 of 5 stars
3.55.04.20.43.02.51.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Boston Scientific Corporation stock logo
BSX
Boston Scientific
3.13
Buy$116.098.67% Upside
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
2.74
Moderate Buy$395.714.41% Upside
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.83
Moderate Buy$813.5756.15% Upside
Zoetis Inc. stock logo
ZTS
Zoetis
3.00
Buy$212.1335.83% Upside

Current Analyst Ratings Breakdown

Latest HCA, ZTS, REGN, and BSX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/23/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$376.00 ➝ $404.00
6/18/2025
Zoetis Inc. stock logo
ZTS
Zoetis
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$165.00 ➝ $160.00
6/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/16/2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$118.00
6/9/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetEqual Weight ➝ Equal Weight$355.00 ➝ $410.00
6/9/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.00
6/5/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.00
6/2/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
6/2/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetOverweight ➝ Overweight$366.00 ➝ $416.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$700.00 ➝ $650.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.00
(Data available from 6/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$16.75B9.44$3.66 per share29.18$14.93 per share7.16
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$70.60B1.29$35.89 per share10.56$2.19 per share173.06
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.20B3.96$45.70 per share11.40$268.50 per share1.94
Zoetis Inc. stock logo
ZTS
Zoetis
$9.26B7.51$7.07 per share22.09$10.57 per share14.77
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$1.85B$1.3777.9833.072.7511.58%18.67%10.38%7/23/2025 (Estimated)
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$5.76B$22.4916.8513.521.318.07%1,063.91%10.10%7/22/2025 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.41B$39.2813.2613.701.9131.94%15.27%11.93%7/30/2025 (Estimated)
Zoetis Inc. stock logo
ZTS
Zoetis
$2.49B$5.5728.0423.142.5927.12%55.48%19.14%8/5/2025 (Estimated)

Latest HCA, ZTS, REGN, and BSX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/23/2025Q2 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.72N/AN/AN/A$4.89 billionN/A
7/22/2025Q2 2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$6.20N/AN/AN/A$18.49 billionN/A
5/6/2025Q1 2025
Zoetis Inc. stock logo
ZTS
Zoetis
$1.40$1.48+$0.08$1.41$2.20 billion$2.22 billion
4/29/2025Q1 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billion
4/25/2025Q1 2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$5.75$6.45+$0.70$6.45$18.26 billion$18.32 billion
4/23/2025Q1 2025
Boston Scientific Corporation stock logo
BSX
Boston Scientific
$0.67$0.75+$0.08$0.45$4.57 billion$4.66 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Boston Scientific Corporation stock logo
BSX
Boston Scientific
N/AN/AN/AN/AN/A
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
$2.880.76%N/A12.81%6 Years
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.520.68%N/A8.96%N/A
Zoetis Inc. stock logo
ZTS
Zoetis
$2.001.28%N/A35.91%14 Years

Latest HCA, ZTS, REGN, and BSX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/22/2025
Zoetis Inc. stock logo
ZTS
Zoetis
quarterly$0.501.2%7/18/20257/18/20259/3/2025
4/25/2025
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
quarterly$0.720.84%6/16/20256/16/20256/30/2025
5/20/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.880.6%5/20/20255/20/20256/6/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.47
1.45
0.88
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
69.07
1.19
1.06
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.09
4.93
4.03
Zoetis Inc. stock logo
ZTS
Zoetis
1.12
1.74
1.04

Institutional Ownership

CompanyInstitutional Ownership
Boston Scientific Corporation stock logo
BSX
Boston Scientific
89.07%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
62.73%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Zoetis Inc. stock logo
ZTS
Zoetis
92.80%

Insider Ownership

CompanyInsider Ownership
Boston Scientific Corporation stock logo
BSX
Boston Scientific
0.50%
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
1.30%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
7.02%
Zoetis Inc. stock logo
ZTS
Zoetis
0.18%
CompanyEmployeesShares OutstandingFree FloatOptionable
Boston Scientific Corporation stock logo
BSX
Boston Scientific
53,0001.48 billion1.47 billionOptionable
HCA Healthcare, Inc. stock logo
HCA
HCA Healthcare
316,000240.57 million237.45 millionOptionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,106107.96 million100.39 millionOptionable
Zoetis Inc. stock logo
ZTS
Zoetis
13,800445.21 million444.41 millionOptionable

Recent News About These Companies

Zoetis Inc. (NYSE:ZTS) Shares Sold by Bessemer Group Inc.
5 Insightful Analyst Questions From Zoetis’s Q1 Earnings Call
ZTS - Zoetis Inc Class A Valuation - Morningstar
Stifel Downgrades Zoetis (ZTS) Stock, Reduces PT
ZTS - Zoetis Inc Class A Key Metrics - Morningstar

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Boston Scientific stock logo

Boston Scientific NYSE:BSX

$106.83 +2.25 (+2.15%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$106.19 -0.64 (-0.60%)
As of 06/27/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

HCA Healthcare stock logo

HCA Healthcare NYSE:HCA

$379.00 +1.34 (+0.35%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$377.59 -1.41 (-0.37%)
As of 06/27/2025 07:36 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

HCA Healthcare, Inc., through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy. The company also operates outpatient health care facilities consisting of freestanding ambulatory surgery centers, freestanding emergency care facilities, urgent care facilities, walk-in clinics, diagnostic and imaging centers, rehabilitation and physical therapy centers, radiation and oncology therapy centers, physician practices, and various other facilities. In addition, it operates behavioral hospitals, which provide therapeutic programs comprising child, adolescent and adult psychiatric care, adolescent and adult alcohol, drug abuse treatment, and counseling services. The company was formerly known as HCA Holdings, Inc. HCA Healthcare, Inc. was founded in 1968 and is headquartered in Nashville, Tennessee.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$521.00 0.00 (0.00%)
Closing price 06/27/2025 04:00 PM Eastern
Extended Trading
$524.00 +3.00 (+0.58%)
As of 06/27/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Zoetis stock logo

Zoetis NYSE:ZTS

$156.17 +0.38 (+0.24%)
Closing price 06/27/2025 03:59 PM Eastern
Extended Trading
$156.17 +0.00 (+0.00%)
As of 06/27/2025 05:38 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.